トラスツズマブ (遺伝子組換え) (JAN);
トラスツズマブ (遺伝子組換え) [トラスツズマブ後続1] (JAN);
トラスツズマブ (遺伝子組換え) [トラスツズマブ後続2] (JAN);
トラスツズマブ (遺伝子組換え) [トラスツズマブ後続3] (JAN);
Trastuzumab (USAN/INN);
Trastuzumab (genetical recombination) (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 1] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 2] (JAN);
Trastuzumab (genetical recombination) [Trastuzumab biosimilar 3] (JAN);
Trastuzumab-pkrb;
Trastuzumab-anns;
Trastuzumab-dkst;
Trastuzumab-dttb;
Trastuzumab-qyyp;
Trastuzumab-anns

HERCEPTIN (Genentech), HERZUMA (Cephalon), KANJINTI (Amgen), OGIVRI (Biocon Biologics), OGIVRI (Mylan Institutional LLC), ONTRUZANT (Organon LLC), TRAZIMERA (Pfizer Laboratories Div Pfizer)

(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR IYPTNGYTRY
ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG GDGFYAMDYW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPG
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS ASFLYSGVPS
RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H147-H203, H264-H324, H370-H428, H229-H'229, H232-H'232, L23-L88, L134-L194, H223-L214)

抗悪性腫瘍薬, 受容体型チロシンキナーゼ阻害薬, 抗HER2抗体

希少疾病用医薬品指定: HER2過剰発現が確認された治癒切除不能な進行・再発の唾液腺癌 [DS:H01508]

ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]

DDI search